"Positive Zotatifin Data Supports An Opportunity In Breast Cancer" - Cantor Fitzgerald Bullish on eFFECTOR Therapeutics (EFTR) With Overweight Rating, $50 Price Target Jun 6, 2022 06:27AM
"Zota is Work in Progress", Focus Remains on Tomi - Stifel Maintains eFFECTOR Therapeutics (EFTR) at Hold Jun 6, 2022 06:07AM
Mizuho Securities Reiterates Buy Rating, $20 Price Target on eFFECTOR Therapeutics (EFTR) Apr 7, 2022 06:09AM
Mizuho Securities Reiterates eFFECTOR Therapeutics (EFTR) a Buy, $20 PT, but Sees Low Cash as Overhang on Shares Mar 17, 2022 06:10AM
eFFECTOR Therapeutics, Inc. (EFTR) PT Lowered to $4 at Stifel, Analyst Reiterates Hold, Awaits Proof-of-Concept tomivosertib Data Mar 16, 2022 07:15PM


Mar 16, 2022 07:12PM Cantor Fitzgerald Reiterates eFFECTOR Therapeutics (EFTR) at Overweight, $50 PT, "Company's Pipeline Remains Underappreciated", Expect Advancements to Move Stock Higher
Jan 25, 2022 06:00AM eFFECTOR's (EFTR) tomi Cohorts Unlikely to Be Positive, Stock is a High Risk, Downgrade to Hold, Cut PT to $6.20 - Stifel